Financial Performance - In 2022, the company's operating revenue was CNY 2,718,134,785.52, a decrease of 1.66% compared to CNY 2,763,962,481.58 in 2021[23] - The net profit attributable to shareholders of the listed company for 2022 was CNY 104,655,073.39, down 44.06% from CNY 187,089,423.86 in 2021[23] - The net profit after deducting non-recurring gains and losses was CNY 87,401,669.09, a decrease of 37.71% compared to CNY 140,304,645.66 in the previous year[23] - Cash flow from operating activities for 2022 was CNY 460,462,582.82, an increase of 5.25% from CNY 437,503,470.18 in 2021[23] - Basic earnings per share decreased by 44.07% to 0.1359 yuan per share in 2022 compared to 0.2430 yuan per share in 2021[25] - The weighted average return on equity fell to 3.56%, a decrease of 3.01 percentage points from 6.57% in 2021[25] Assets and Dividends - The total assets at the end of 2022 were CNY 4,131,067,057.38, reflecting a 1.33% increase from CNY 4,076,677,070.74 at the end of 2021[24] - The net assets attributable to shareholders of the listed company at the end of 2022 were CNY 2,970,077,495.32, up 1.47% from CNY 2,926,964,820.93 at the end of 2021[24] - The company plans to distribute a cash dividend of CNY 0.5 per 10 shares, totaling CNY 38,500,001.15, based on a total share capital of 770,000,023 shares[6] Strategic Focus and R&D - The company focused on pediatric products, generic drugs, and innovation investments as part of its strategic direction[30] - The company plans to enhance R&D efficiency and accelerate the introduction of new products in pediatric and chronic disease sectors[31] - The company is committed to a "Pediatric First" strategy, focusing on innovative marketing and channel transformation to enhance product development and service models[34] - The company’s research and development efforts are aligned with national strategies to promote health and traditional medicine, aiming for high-quality development in the pharmaceutical sector[38] - The company aims to strengthen its market position in the traditional Chinese medicine sector, focusing on proprietary and specialty products, with an emphasis on pediatric traditional Chinese medicine[41] Market Performance - The company’s OTC sales segment saw a market share increase for its flagship product Dinggui Er Qi贴, reaching 17.8%, a year-on-year increase of 0.8 percentage points, while sales for Yiyang Jianpi Gel reached 55.26 million yuan, a 42% year-on-year growth[35] - RX sales for the company’s pediatric products, particularly the Children's Throat Relief Oral Liquid, achieved 80.65 million yuan in revenue, a 89% year-on-year increase, amidst a competitive procurement environment[36] - The company’s brand exposure reached a historical high of 12.2 billion in 2022, enhancing brand visibility through various marketing strategies[36] Cost Management and Efficiency - The production center optimized production processes and implemented cost management to improve efficiency and reduce costs[31] - The company's sales expenses decreased by 13.98% to 897 million RMB, attributed to a reduction in marketing expenses[55] - Research and development expenses fell by 16.87% to 131 million RMB, reflecting a decrease in R&D investment[55] - The company’s operating costs rose by 11.35% to 1.199 billion RMB, mainly due to increased costs in pharmaceutical wholesale[55] Regulatory and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[8] - The company has not proposed any stock issuance or capital reserve transfer to increase share capital for the year 2022[6] - The company strictly adheres to information disclosure regulations, ensuring timely, fair, and accurate information is available to all shareholders[124] - The company has not experienced significant differences in governance compared to regulatory requirements, ensuring compliance[125] Environmental Responsibility - The company invested CNY 8.9 million in environmental protection initiatives during the reporting period[159] - The wastewater treatment station at Ruicheng Industrial Park has a daily processing capacity of 1,000 tons, utilizing hydrolysis acidification and anaerobic tower biological oxidation processes, meeting the GB21905-2008 standard for pharmaceutical wastewater discharge[166] - The company has implemented a comprehensive pollution prevention strategy, including the construction of advanced wastewater treatment facilities and the installation of emission monitoring systems[166][167] Governance and Management - The company has a supervisory board consisting of 3 members, including 1 employee representative, complying with relevant laws and regulations[123] - The performance evaluation of senior management is conducted annually by the Compensation and Assessment Committee, ensuring accountability[123] - The company’s board of directors and senior management have maintained stable shareholdings, with no changes reported during the period[129] - The company has established a structured remuneration system for its directors and senior management, ensuring alignment with performance evaluations[136]

Financial Performance - The company's operating revenue for Q1 2023 was ¥800,499,169.06, representing a year-on-year increase of 15.30%[5] - The net profit attributable to shareholders for the same period was ¥107,419,836.15, reflecting a significant increase of 50.47% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.1395, which is an increase of 50.47% year-on-year[6] - Total revenue for Q1 2023 reached ¥800,499,169.06, an increase of 15.3% compared to ¥694,295,635.07 in Q1 2022[17] - Operating profit for Q1 2023 was ¥130,496,444.86, up 48.4% from ¥87,848,278.81 in Q1 2022[18] - Net profit for Q1 2023 was ¥108,529,546.66, representing a 55% increase from ¥70,043,628.72 in Q1 2022[18] - Earnings per share for Q1 2023 were ¥0.1395, compared to ¥0.0927 in Q1 2022, reflecting a growth of 50.5%[19] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥94,425,180.27, marking an impressive increase of 88.76% year-on-year[5] - Operating cash inflow for Q1 2023 was CNY 699,369,435.86, an increase of 16.1% from CNY 602,384,142.98 in Q1 2022[20] - Net cash flow from operating activities for Q1 2023 was CNY 94,425,180.27, up 88.5% from CNY 50,025,100.38 in Q1 2022[21] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 711,175,799.49, compared to CNY 481,228,091.53 at the end of Q1 2022, representing a 47.7% increase[22] - The company reported a cash balance of RMB 761,097,151.88, up from RMB 668,503,421.96, indicating stronger liquidity[13] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,212,374,707.12, a 1.97% increase from the end of the previous year[6] - The total current assets amounted to RMB 2,060,915,179.43, an increase from RMB 1,954,333,997.61 as of December 31, 2022[13] - The total non-current assets decreased to RMB 2,151,459,527.69 from RMB 2,176,733,059.77, indicating a reduction in long-term investments[14] - Total liabilities increased to RMB 2,060,915,179.43, reflecting the company's ongoing financing activities[14] - Total liabilities decreased to ¥1,097,217,381.19 in Q1 2023 from ¥1,124,425,007.43 in Q1 2022, a reduction of approximately 2.4%[17] - Total equity increased to ¥3,115,157,325.93 in Q1 2023 from ¥3,006,642,049.95 in Q1 2022, marking a growth of about 3.6%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 56,133[11] - The largest shareholder, Shanshi Yabao Investment Group Co., Ltd., holds 94,300,000 shares, accounting for 12.25% of total shares[11] Expenses and Cost Management - Research and development expenses for Q1 2023 were ¥27,263,743.67, up from ¥25,593,278.84 in Q1 2022, indicating a 6.5% increase[17] - Sales expenses rose to ¥238,759,501.81 in Q1 2023, compared to ¥223,202,616.75 in Q1 2022, reflecting a growth of 7%[17] - The company reported a significant reduction in sales expenses, which decreased to ¥11,538,915.78 from ¥13,592,317.90 in Q1 2022, indicating improved cost management[25] - The company reported a decrease in financial expenses to ¥2,250,799.69 in Q1 2023 from ¥3,876,165.30 in Q1 2022, a reduction of approximately 42%[17] Government Subsidies - The company reported a significant increase in government subsidies recognized in profit or loss, which rose by 226.50% year-on-year[9] - Other income for Q1 2023 was ¥8,034,006.80, significantly higher than ¥2,460,643.90 in Q1 2022, representing a growth of 226.5%[17] Future Plans - The company plans to continue expanding its market presence and investing in new product development[25] - The company has not reported any significant new product developments or market expansions in the current quarter[12]

2022 年第三季度报告 亚宝药业集团股份有限公司 2022 年第三季度报告 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告 期比上 | | 年初至报告 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期 | 年初至报告期末 | 期末比上年 | | | | 增减变 | | 同期增减变 | | | | 动幅度 | | 动幅度(%) | | | | (%) | | | | 营业收入 | 678,765,945.93 | -8.37 | 1,972,686,963.41 | -10.56 | | 归属于上市公司股 东的净利润 | 6,445,657.72 | -85.97 | 106,848,070.15 | -26.45 | 证券代码：600351 证券简称：亚宝药业 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 ...

2022 年半年度报告 公司代码：600351 公司简称：亚宝药业 亚宝药业集团股份有限公司 2022 年半年度报告 1 / 162 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人任武贤、主管会计工作负责人左哲峰及会计机构负责人（会计主管人员）左哲峰 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质性承诺，请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的 ...

2021 年年度报告 二、 公司全体董事出席董事会会议。 三、 致同会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人任武贤、主管会计工作负责人左哲峰及会计机构负责人（会计主管人员）左哲峰 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司代码：600351 公司简称：亚宝药业 亚宝药业集团股份有限公司 2021 年年度报告 1 / 221 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露年度报告的真实性、准确性和完整性 经致同会计师事务所（特殊普通合伙）审计，公司2021年实现归属于母 ...

2021 年年度报告 公司代码：600351 公司简称：亚宝药业 亚宝药业集团股份有限公司 2021 年年度报告 1 / 221 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 致同会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人任武贤、主管会计工作负责人左哲峰及会计机构负责人（会计主管人员）左哲峰 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经致同会计师事务所（特殊普通合伙）审计，公司2021年实现归属于母公司所有者的净利润 为187,089,423.86元，可供股东分配的利润为989,071,712.65元。 公司2021年度利润分配预案为：以公司总股本770,000,023股为基数，向全体股东每10股派发 现金红利0.8元（含税），共计分配现金红利61,600,001.84元，剩余未分配利润结转下一年度。 不送 ...

2022 年第一季度报告 证券代码：600351 证券简称：亚宝药业 亚宝药业集团股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 | | --- | --- | --- | | | | 变动幅度(%) | | 营业收入 | 694,295,635.07 | -12.47 | | 归属于上市公司股东的净利润 | 71,387,262.01 | 10.28 | | 归属于上市公司股东的扣除非经常性损益的 | 69,871,479.94 | 16.00 | ...

[Major Financial Data](index=1&type=section&id=Item%20I.%20Major%20Financial%20Data) [Key Accounting Data and Financial Indicators](index=1&type=section&id=Item%28I%29.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved **2.206 billion Yuan** in operating revenue and **145 million Yuan** in net profit attributable to shareholders in the first three quarters of 2021, growing by 19.13% and 58.09% respectively, with strong third-quarter performance Key Financial Indicators for the First Three Quarters of 2021 | Indicator | Year-to-Date (Yuan) | Year-on-Year Growth (%) | | :--- | :--- | :--- | | Operating Revenue | 2,205,654,088.29 | 19.13% | | Net Profit Attributable to Shareholders | 145,274,815.46 | 58.09% | | Net Profit Attributable to Shareholders (Excl. Non-recurring) | 124,305,817.40 | 80.65% | | Net Cash Flow from Operating Activities | 274,607,162.87 | 16.58% | | Basic Earnings Per Share | 0.1887 Yuan/share | 58.17% | Key Financial Indicators for Q3 2021 | Indicator | Current Period (Q3) (Yuan) | Year-on-Year Growth (%) | | :--- | :--- | :--- | | Operating Revenue | 740,749,708.96 | 5.88% | | Net Profit Attributable to Shareholders | 45,949,685.70 | 48.95% | | Net Profit Attributable to Shareholders (Excl. Non-recurring) | 36,600,113.22 | 68.02% | Key Balance Sheet Indicators as of September 30, 2021 | Indicator | Period-End Balance (Yuan) | Growth from End of Previous Year (%) | | :--- | :--- | :--- | | Total Assets | 4,136,535,153.47 | 3.05% | | Total Equity Attributable to Shareholders | 2,885,174,862.79 | 3.84% | [Non-recurring Gains and Losses Items and Amounts](index=2&type=section&id=Item%28II%29.%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for the first three quarters of 2021 were **20.969 million Yuan**, primarily driven by **22.1922 million Yuan** in government grants Key Non-recurring Gains and Losses Items for the First Three Quarters of 2021 | Item | Year-to-Date Amount (Yuan) | | :--- | :--- | | Government Grants Recognized in Current Period P&L | 22,192,224.04 | | Other Non-operating Income and Expenses | -4,636,769.29 | | Reversal of Impairment Provisions for Receivables | 3,975,934.93 | | Capital Occupation Fees Received from Non-financial Enterprises | 2,407,803.87 | | Fair Value Changes in Trading Financial Assets/Liabilities | 1,723,869.87 | | **Total** | **20,968,998.06** | [Analysis of Changes in Key Financial Indicators](index=4&type=section&id=Item%28III%29.%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Significant performance growth in the first three quarters of 2021 is attributed to increased sales of core high-margin products like Dingguier Umbilical Paste and Xiaozhong Zhitong Paste - Operating revenue increased by **19.13%** year-on-year, primarily due to increased sales volume of key products such as Dingguier Umbilical Paste and Xiaozhong Zhitong Paste[10](index=10&type=chunk) - Net profit attributable to shareholders and net profit attributable to shareholders after deducting non-recurring gains and losses significantly increased by **58.09%** and **80.65%** respectively, mainly benefiting from increased revenue and a higher proportion of sales from high-margin products like Dingguier Umbilical Paste and Xiaozhong Zhitong Paste[10](index=10&type=chunk) [Shareholder Information](index=4&type=section&id=Item%20II.%20Shareholder%20Information) [Shareholding Status of Shareholders](index=4&type=section&id=Item%28I%29.%20Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Shareholding%20Table) As of September 30, 2021, the company had **45,373** common shareholders, with Shanxi Yabao Investment Group Co., Ltd. as the largest, holding **12.25%** of shares, some pledged - As of the end of the reporting period, the company had a total of **45,373** common shareholders[12](index=12&type=chunk) Top Ten Shareholders' Shareholding Status | Shareholder Name | Shareholding Ratio (%) | Number of Shares Held | Share Status | | :--- | :--- | :--- | :--- | | Shanxi Yabao Investment Group Co., Ltd. | 12.25 | 94,300,000 | Pledged 53,200,000 | | Guangdong Jin Ya Relief Equity Investment Partnership | 6.18 | 47,600,000 | None | | Shanxi Provincial Economic Construction Investment Group Co., Ltd. | 3.36 | 25,891,756 | None | | Lingding No. 17 Private Securities Investment Fund | 2.17 | 16,699,920 | None | | Yinwan Quanying No. 13 Private Securities Investment Fund | 1.52 | 11,700,000 | None | [Other Important Reminders](index=6&type=section&id=Item%20III.%20Other%20Important%20Reminders) [Other Important Information](index=6&type=section&id=Other%20Important%20Information%20Regarding%20the%20Company%27s%20Operating%20Performance%20During%20the%20Reporting%20Period%20Requiring%20Investor%20Attention) The company confirms no other important information regarding its operating performance requires special investor attention during the reporting period - The company confirms that there is no other important information regarding its operating performance during the reporting period that requires investor attention[15](index=15&type=chunk) [Quarterly Financial Statements](index=6&type=section&id=Item%20IV.%20Quarterly%20Financial%20Statements) [Type of Audit Opinion](index=6&type=section&id=Item%28I%29.%20Type%20of%20Audit%20Opinion) The company's financial statements for the third quarter of 2021 are unaudited - The financial statements for this quarter are unaudited[15](index=15&type=chunk) [Financial Statements](index=7&type=section&id=Item%28II%29.%20Financial%20Statements) As of September 30, 2021, total assets were **4.137 billion Yuan**, with first three quarters' operating revenue of **2.206 billion Yuan**, net profit of **145 million Yuan**, and net operating cash flow of **275 million Yuan** [Consolidated Balance Sheet](index=7&type=section&id=Consolidated%20Balance%20Sheet) As of September 30, 2021, total assets were **4.137 billion Yuan** (up **3.05%**), and equity attributable to owners of the parent was **2.885 billion Yuan** (up **3.84%**), with cash increasing to **467 million Yuan** Key Balance Sheet Item Changes | Item | September 30, 2021 (Yuan) | December 31, 2020 (Yuan) | Change Rate | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 467,089,145.91 | 350,412,333.61 | 33.29% | | Accounts Receivable | 519,951,763.88 | 468,930,397.71 | 10.88% | | Inventories | 457,382,535.23 | 498,010,506.09 | -8.16% | | Total Assets | 4,136,535,153.47 | 4,014,286,809.26 | 3.05% | | Short-term Borrowings | 610,634,138.88 | 628,318,703.73 | -2.81% | | Total Liabilities | 1,211,630,807.89 | 1,195,932,361.84 | 1.31% | | Equity Attributable to Owners of the Parent | 2,885,174,862.79 | 2,778,411,394.41 | 3.84% | [Consolidated Income Statement](index=9&type=section&id=Consolidated%20Income%20Statement) Total operating revenue for the first three quarters of 2021 grew **19.13%** to **2.206 billion Yuan**, with R&D expenses up **88.32%** to **114 million Yuan**, and net profit attributable to owners of the parent increasing **58.09%** to **145 million Yuan** Key Income Statement Item Changes (Q1-Q3 2021 vs Q1-Q3 2020) | Item | Jan-Sep 2021 (Yuan) | Jan-Sep 2020 (Yuan) | Change Rate | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 2,205,654,088.29 | 1,851,474,001.29 | 19.13% | | Operating Cost | 881,406,982.64 | 734,135,209.03 | 20.06% | | Selling Expenses | 817,881,580.63 | 710,561,527.03 | 15.10% | | Research and Development Expenses | 114,483,700.34 | 60,789,397.35 | 88.32% | | Financial Expenses | 13,859,624.64 | 25,336,838.61 | -45.30% | | Total Profit | 166,254,070.61 | 106,800,390.53 | 55.67% | | Net Profit Attributable to Owners of the Parent | 145,274,815.46 | 91,891,051.07 | 58.09% | [Consolidated Cash Flow Statement](index=12&type=section&id=Consolidated%20Cash%20Flow%20Statement) Net cash flow from operating activities was **275 million Yuan** (up **16.58%**) in the first three quarters of 2021; net cash outflow from investing activities expanded to **103 million Yuan**, while financing cash outflow significantly narrowed Key Cash Flow Statement Items (Q1-Q3 2021 vs Q1-Q3 2020) | Item | Jan-Sep 2021 (Yuan) | Jan-Sep 2020 (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 274,607,162.87 | 235,544,718.83 | | Net Cash Flow from Investing Activities | -103,417,346.56 | -70,562,874.59 | | Net Cash Flow from Financing Activities | -67,934,448.73 | -289,389,708.17 | | Net Increase in Cash and Cash Equivalents | 103,224,987.61 | -124,258,327.70 | [Adoption and Adjustment of New Lease Standards](index=14&type=section&id=Item%28III%29.%20Adjustments%20to%20Beginning-of-Year%20Financial%20Statements%20Upon%20First-time%20Adoption%20of%20New%20Lease%20Standards%20in%202021) Effective January 1, 2021, the company adopted new lease standards, adjusting only opening 2021 financial statements to recognize **2.5021 million Yuan** in right-of-use assets and **2.4170 million Yuan** in lease liabilities - The company adopted the new lease standards on January 1, 2021, using a simplified approach without retrospective adjustment of comparable period information, only adjusting the opening balances for 2021[30](index=30&type=chunk) Impact of Adopting New Lease Standards on the January 1, 2021 Balance Sheet | Adjustment Item | Adjusted Amount (Yuan) | | :--- | :--- | | **Assets** | | | Right-of-Use Assets | +2,502,083.59 | | Prepayments | -85,132.73 | | **Liabilities** | | | Non-current Liabilities Due Within One Year | +1,138,351.06 | | Lease Liabilities | +1,278,599.80 |

1 / 169 2021 年半年度报告 重要提示 2021 年半年度报告 公司代码：600351 公司简称：亚宝药业 亚宝药业集团股份有限公司 2021 年半年度报告 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质性承诺，请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告中详细 描述在生产经营过程中可能面临的各种风险及应对措施，敬请查阅"第三节 管理层讨论与分析" 之"五、其他披露事项"之"（一）可能面对的风险"部分 ...

2021 年第一季度报告 公司代码：600351 公司简称：亚宝药业 亚宝药业集团股份有限公司 2021 年第一季度报告 1 / 26 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2021 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 谭勇 | 独立董事 | 因公原因 | 余春江 | 1.3 公司负责人任武贤 、主管会计工作负责人左哲峰及会计机构负责人（会计主管人员）左哲 峰保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | --- | --- | --- | --- | | ...